Core Viewpoint - Zhonghui Biotech-B (02627) has experienced a significant stock price increase since its listing, reflecting strong market interest and investor confidence in its vaccine development capabilities [1] Company Overview - Zhonghui Biotech focuses on the research, manufacturing, and commercialization of vaccines [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine, approved for individuals aged three and above, and an in-development lyophilized human rabies vaccine [1] - Additionally, Zhonghui Biotech is working on 11 other vaccine candidates [1] Market Performance - The stock surged nearly 158% on its first day of trading and continued to rise over 20% the following morning, with a current price of 39.72 HKD [1] - The total market capitalization of Zhonghui Biotech has surpassed 15 billion HKD [1] - The IPO public offering was oversubscribed by over 4000 times, with total subscription amounts exceeding 200 billion HKD, making it the "super subscription king" in the Hong Kong biotech sector for 2023 [1]
港股异动 | 中慧生物-B(02627)上市次日再涨超20% 昨日飙升近158% 总市值突破150亿港元